Company / SG&A Expense
PLIANT THERAPEUTICS, INC. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$59.1M
FY2025
5-year range
$10.9M / $59.1M
FY2021-FY2025
Trend
+47.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $28M to $59M over the past 2 years.
Based on SEC 10-K filings.
$59M in FY2025 with a 5-year CAGR of +40.1%.
Increased from $28M to $59M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +28.9%
- 5-Year CAGR
- +40.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +40.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 47.8% year-over-year.
- Lowest sg&a expense in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -4.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.1M | +47.8% |
| FY2024 | $39.9M | +45.0% |
| FY2023 | $27.6M | +0.0% |
| FY2022 | $27.6M | +152.1% |
| FY2021 | $10.9M | +0.0% |
| FY2020 | $10.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026